The Experience of Screening for SCID
Key facts
- Who runs it
- King's College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 90 people, planned
- Started
- 9 Nov 2022
- Expected to end
- 31 Mar 2029
- Type of study
- Observational, 6 groups
- Treatments tested
- SCID Screening
- Record updated
- 14 December 2022
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participants must be at least 18 years of age. Participants must be able to understand the purpose and implications of the research study
- Where participants are speakers of languages other than English, the research team will arrange a translator
Who cannot take part
- Where a child dies after recruitment to the project the team will sensitively check whether the parents wish to continue participation to enable their views to be included
This trial is currently available in United Kingdom.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This project will evaluate the impact of including Severe Combined Immunodeficiency into the newborn bloodspot screening panel. It will recruit parents and health professionals primarily from the sites where this new form of screening is being trialled well as additional sites where clinicians will be involved in the care of these babies and comparator groups are needed.
Read full original descriptionShow less
The proposed work will consist of two work packages. The first, a mixed-methods study conducted with families from the point of screening information being returned through to the child's fifth birthday. The second, a qualitative interview study conducted with health professionals during the clinical evaluation phase of the national pilot programme.
The 6 groups in the trial
- Positive NBS for SCID
Parents whose baby was referred to an immunologist due their SCID screening result (minimum n= 10-25)
Treatment: SCID Screening
- Normal NBS result
Parents who received a normal screening result (minimum n=10-25)
Treatment: SCID Screening
- False positive NBS result
Parents who have received a false positive result elsewhere in screening (minimum n=2-10)
- CFSPID Designation
Parents who received a CFSPID result (minimum n=\~10)
- SCID via family history or clinical presentation
Parents whose baby was identified with SCID due to family history or clinical presentation (minimum n=10)
- Parents whose babies have died
Parents who have received an abnormal screening result (T cell receptor excision circles (TRECs) or who were identified with SCID due to family history or clinical presentation and whose baby has subsequently died (n=\~10)
Treatment: SCID Screening
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Exploring Parents' and Health Professionals' Experiences of Screening for Severe Combined Immunodeficiency
- Record updated
- 14 December 2022